Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-485.95%
operating margin TTM
-515.65%
revenue TTM
74.89 Million
revenue per share TTM
1.09$
valuation ratios | |
|---|---|
| pe ratio | -6.20 |
| peg ratio | 0.54 |
| price to book ratio | 6.37 |
| price to sales ratio | 29.44 |
| enterprise value multiple | -6.19 |
| price fair value | 6.37 |
profitability ratios | |
|---|---|
| gross profit margin | 94.08% |
| operating profit margin | -515.65% |
| pretax profit margin | -485.74% |
| net profit margin | -485.95% |
| return on assets | -81.75% |
| return on equity | -76.13% |
| return on capital employed | -98.52% |
liquidity ratios | |
|---|---|
| current ratio | 7.18 |
| quick ratio | 7.11 |
| cash ratio | 2.48 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 307.20 |
| operating cycle | 316.21 |
| days of payables outstanding | 4,079.35 |
| cash conversion cycle | -3,763.14 |
| receivables turnover | 40.52 |
| payables turnover | 0.09 |
| inventory turnover | 1.19 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.08 |
| debt equity ratio | 0.11 |
| long term debt to capitalization | 0.10 |
| total debt to capitalization | 0.10 |
| interest coverage | -15,594.86 |
| cash flow to debt ratio | -9.90 |
cash flow ratios | |
|---|---|
| free cash flow per share | -3.04 |
| cash per share | 2.91 |
| operating cash flow per share | -3.01 |
| free cash flow operating cash flow ratio | 1.01 |
| cash flow coverage ratios | -9.90 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -78.76 |
Frequently Asked Questions
When was the last time EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) reported earnings?
EyePoint Pharmaceuticals, Inc. (EYPT) published its most recent earnings results on 06-11-2025.
What is EyePoint Pharmaceuticals, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)'s trailing twelve months ROE is -76.13%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. EyePoint Pharmaceuticals, Inc. (EYPT) currently has a ROA of -81.75%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did EYPT's net profit margin stand at?
EYPT reported a profit margin of -485.95% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is EYPT's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 7.18 in the most recent quarter. The quick ratio stood at 7.11, with a Debt/Eq ratio of 0.11.